United Therapeutics Stock Market Capitalization
| UTH Stock | EUR 280.50 3.20 1.15% |
United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.
United |
United Therapeutics Company Market Capitalization Analysis
United Therapeutics' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current United Therapeutics Market Capitalization | 10.75 B |
Most of United Therapeutics' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of United Therapeutics is about 10.75 B. This is 16.96% lower than that of the Healthcare sector and 126.68% higher than that of the Biotechnology industry. The market capitalization for all Germany stocks is 43.53% higher than that of the company.
United Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.United Therapeutics is currently under evaluation in market capitalization category among its peers.
United Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.38 % | |||
| Operating Margin | 0.51 % | |||
| Current Valuation | 10.24 B | |||
| Shares Outstanding | 46.3 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 98.21 % | |||
| Price To Earning | 7.31 X | |||
| Price To Book | 2.73 X | |||
| Price To Sales | 6.30 X | |||
| Revenue | 1.94 B | |||
| Gross Profit | 1.78 B | |||
| EBITDA | 1.03 B | |||
| Net Income | 727.3 M | |||
| Cash And Equivalents | 1.79 B | |||
| Cash Per Share | 40.73 X | |||
| Total Debt | 800 M | |||
| Debt To Equity | 41.30 % | |||
| Current Ratio | 4.62 X | |||
| Book Value Per Share | 104.20 X | |||
| Cash Flow From Operations | 802.5 M | |||
| Earnings Per Share | 13.25 X | |||
| Price To Earnings To Growth | 1.00 X | |||
| Target Price | 231.89 | |||
| Number Of Employees | 965 | |||
| Beta | 0.63 | |||
| Market Capitalization | 10.75 B | |||
| Total Asset | 6.04 B | |||
| Z Score | 7.8 | |||
| Net Asset | 6.04 B |
About United Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in United Stock
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in United Stock please use our How to Invest in United Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.